특수 제네릭 의약품 시장 - 산업 규모, 점유율, 동향, 기회, 예측 : 투여 경로, 적응증, 유통 채널, 지역별 경쟁(2021-2031년)

The Global Specialty Generics Market is set for substantial growth, projected to increase from USD 56.69 Billion in 2025 to USD 99.12 Billion by 2031 at a 9.76% CAGR. This sector focuses on bioequivalent versions of highly complex pharmaceutical products, such as injectables and biologics, used to treat chronic or rare conditions like cancer and autoimmune disorders, often requiring specialized handling. The market's expansion is fundamentally driven by the escalating prevalence of chronic diseases and the critical imperative for healthcare cost containment, particularly following the patent expiration of major originator drugs. The economic value of affordable alternatives is significant, with generic and biosimilar medicines saving the U.S. healthcare system $467 billion in 2024.

Market Driver

A major catalyst for the Global Specialty Generics Market is the impending patent cliff, with approximately $236 billion worth of pharmaceutical products facing generic and biosimilar competition between 2025 and 2030, creating immense opportunities for generic manufacturers to introduce bioequivalent alternatives and alleviate the financial burden of expensive originator therapies. The global increase in complex chronic and rare diseases further amplifies demand, with 76.4% of U.S. adults reporting one or more chronic conditions in 2023, driving manufacturers like Sandoz to expand global operations, having delivered over 902 million patient treatments across more than 100 countries.

Market Challenge

Despite this robust growth potential, the Global Specialty Generics Market faces considerable challenges, primarily stemming from a rigorous regulatory landscape. Unlike standard oral formulations, the development of bioequivalent injectables and biologics requires intricate manufacturing processes and extensive clinical trials, imposing significant financial and technical burdens. These elevated standards limit the number of capable manufacturers, creating a bottleneck that delays the availability of cost-effective treatments and restricts market expansion. A telling statistic reveals that while 118 biologics are expected to lose patent exclusivity over the next decade, only 12 of these molecules had biosimilars in development in 2025, highlighting how regulatory complexity and high development costs deter the initiation of new programs.

Market Trends

In response to these market dynamics, a key trend sees market players increasingly forming strategic alliances and engaging in mergers to share risks, leverage expertise in regulatory affairs and global distribution, and navigate the substantial capital and technical complexities of commercializing biosimilars and specialty injectables. This consolidation accelerates market entry and expands commercial reach, as exemplified by Biocon Biologics exceeding $1 billion in annual revenue post-integration of Viatris' biosimilars business. Concurrently, manufacturers are strategically expanding their portfolios into complex generics like biosimilars, peptides, and long-acting injectables to counter pricing pressures on oral solid dosages and secure more sustainable revenue streams with less competitive intensity, a shift evidenced by Sandoz's global biosimilar pipeline growing to 28 molecules.

Key Market Players

• Teva Pharmaceuticals Industries Ltd
• Viatris Inc.
• Novartis AG
• Hikma Pharmaceuticals PLC
• Bausch Health Companies Inc.
• Dr. Reddy's Laboratories Ltd.
• Endo Pharmaceuticals Inc.
• Apotex Corporation
• Sun Pharmaceutical Industries Ltd
• STADA Arzneimittel AG

Report Scope

In this report, the Global Specialty Generics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Specialty Generics Market, By Route of Administration

• Injectable
• Oral
• others

Specialty Generics Market, By Indication

• Oncology
• Autoimmune Diseases
• Infectious Diseases
• others

Specialty Generics Market, By Distribution Channel

• Retail Pharmacies
• Specialty Pharmacies
• Hospital Pharmacies

Specialty Generics Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Specialty Generics Market.

Available Customizations:

Global Specialty Generics Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Specialty Generics Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Route of Administration (Injectable, Oral, others)
  • 5.2.2. By Indication (Oncology, Autoimmune Diseases, Infectious Diseases, others)
  • 5.2.3. By Distribution Channel (Retail Pharmacies, Specialty Pharmacies, Hospital Pharmacies)
  • 5.2.4. By Region
  • 5.2.5. By Company (2025)
• 5.3. Market Map

6. North America Specialty Generics Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Route of Administration
  • 6.2.2. By Indication
  • 6.2.3. By Distribution Channel
  • 6.2.4. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Specialty Generics Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Route of Administration
      • 6.3.1.2.2. By Indication
      • 6.3.1.2.3. By Distribution Channel
  • 6.3.2. Canada Specialty Generics Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Route of Administration
      • 6.3.2.2.2. By Indication
      • 6.3.2.2.3. By Distribution Channel
  • 6.3.3. Mexico Specialty Generics Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Route of Administration
      • 6.3.3.2.2. By Indication
      • 6.3.3.2.3. By Distribution Channel

7. Europe Specialty Generics Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Route of Administration
  • 7.2.2. By Indication
  • 7.2.3. By Distribution Channel
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Specialty Generics Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Route of Administration
      • 7.3.1.2.2. By Indication
      • 7.3.1.2.3. By Distribution Channel
  • 7.3.2. France Specialty Generics Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Route of Administration
      • 7.3.2.2.2. By Indication
      • 7.3.2.2.3. By Distribution Channel
  • 7.3.3. United Kingdom Specialty Generics Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Route of Administration
      • 7.3.3.2.2. By Indication
      • 7.3.3.2.3. By Distribution Channel
  • 7.3.4. Italy Specialty Generics Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Route of Administration
      • 7.3.4.2.2. By Indication
      • 7.3.4.2.3. By Distribution Channel
  • 7.3.5. Spain Specialty Generics Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Route of Administration
      • 7.3.5.2.2. By Indication
      • 7.3.5.2.3. By Distribution Channel

8. Asia Pacific Specialty Generics Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Route of Administration
  • 8.2.2. By Indication
  • 8.2.3. By Distribution Channel
  • 8.2.4. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Specialty Generics Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Route of Administration
      • 8.3.1.2.2. By Indication
      • 8.3.1.2.3. By Distribution Channel
  • 8.3.2. India Specialty Generics Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Route of Administration
      • 8.3.2.2.2. By Indication
      • 8.3.2.2.3. By Distribution Channel
  • 8.3.3. Japan Specialty Generics Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Route of Administration
      • 8.3.3.2.2. By Indication
      • 8.3.3.2.3. By Distribution Channel
  • 8.3.4. South Korea Specialty Generics Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Route of Administration
      • 8.3.4.2.2. By Indication
      • 8.3.4.2.3. By Distribution Channel
  • 8.3.5. Australia Specialty Generics Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Route of Administration
      • 8.3.5.2.2. By Indication
      • 8.3.5.2.3. By Distribution Channel

9. Middle East & Africa Specialty Generics Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Route of Administration
  • 9.2.2. By Indication
  • 9.2.3. By Distribution Channel
  • 9.2.4. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Specialty Generics Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Route of Administration
      • 9.3.1.2.2. By Indication
      • 9.3.1.2.3. By Distribution Channel
  • 9.3.2. UAE Specialty Generics Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Route of Administration
      • 9.3.2.2.2. By Indication
      • 9.3.2.2.3. By Distribution Channel
  • 9.3.3. South Africa Specialty Generics Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Route of Administration
      • 9.3.3.2.2. By Indication
      • 9.3.3.2.3. By Distribution Channel

10. South America Specialty Generics Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Route of Administration
  • 10.2.2. By Indication
  • 10.2.3. By Distribution Channel
  • 10.2.4. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Specialty Generics Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Route of Administration
      • 10.3.1.2.2. By Indication
      • 10.3.1.2.3. By Distribution Channel
  • 10.3.2. Colombia Specialty Generics Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Route of Administration
      • 10.3.2.2.2. By Indication
      • 10.3.2.2.3. By Distribution Channel
  • 10.3.3. Argentina Specialty Generics Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Route of Administration
      • 10.3.3.2.2. By Indication
      • 10.3.3.2.3. By Distribution Channel

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Specialty Generics Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Teva Pharmaceuticals Industries Ltd
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Viatris Inc.
• 15.3. Novartis AG
• 15.4. Hikma Pharmaceuticals PLC
• 15.5. Bausch Health Companies Inc.
• 15.6. Dr. Reddy's Laboratories Ltd.
• 15.7. Endo Pharmaceuticals Inc.
• 15.8. Apotex Corporation
• 15.9. Sun Pharmaceutical Industries Ltd
• 15.10. STADA Arzneimittel AG

16. Strategic Recommendations

17. About Us & Disclaimer